Biosimilar Battlefield: Celltrion Forecasts
This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...
469 Views
Biosimilar Battlefield: Samsung Bioepis Forecast
This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...
503 Views
Surveying The Biosimilar Battlefield
The biosimilar market has been of particular interest to us in light of the high expectations set for Samsung Biologics Co., Ltd (207940 KS) and...
690 Views
Celltrion Has Potential Manufacturing Headaches
A Form 483 from the USFDA (attached) that criticizes aspects of Celltrion Inc (068270 KS)'s manufacturing facility in Incheon has surfaced in the...
471 Views
More Discussions on Impacts of Celltrion's KOSPI200 Inclusion
Celltrion Inc (068270 KS) said in a regulatory filing that it will have EGM at 10 AM on Aug 29 to decide whether it will move to KOSPI. Below is...
492 Views